Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. (Q33609699)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. |
scientific article |
Statements
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial (English)
Timothy M Nywening
Andrea Wang-Gillam
Dominic E Sanford
Brian A Belt
Roheena Z Panni
Brian M Cusworth
Adetunji T Toriola
Rebecca K Nieman
Lori A Worley
Motoyo Yano
A Craig Lockhart
Rama Suresh
Benjamin R Tan
Ryan C Fields
Steven M Strasberg
William G Hawkins
David G DeNardo
S Peter Goedegebuure
David C Linehan